Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
Frequently Asked Questions About Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
How can investors stay updated on Recursion Pharmaceuticals?
Investors can stay updated on Recursion Pharmaceuticals by following the company's official website, subscribing to press releases, and keeping an eye on financial news related to the biopharmaceutical sector. Additionally, Recursion participates in industry conferences and investor calls, which provide insights into its ongoing projects and strategic direction.
How does Recursion ensure data security?
Recursion Pharmaceuticals prioritizes data security through rigorous protocols and technologies that safeguard its proprietary information and research data. The company employs advanced cybersecurity measures and adheres to industry best practices to protect sensitive data from unauthorized access and breaches.
How does Recursion measure success?
Recursion Pharmaceuticals measures success through various metrics, including the advancement of its drug candidates through clinical trials, partnerships forged within the industry, the impact of its technologies on accelerating drug discovery, and ultimately the positive health outcomes achieved for patients through its therapies.
How does Recursion Pharmaceuticals collaborate with other organizations?
Recursion Pharmaceuticals actively collaborates with academic institutions, pharmaceutical companies, and other biotech firms to enhance its drug discovery efforts. These partnerships often involve sharing resources, expertise, and data, allowing for a synergistic approach to tackling complex medical challenges and accelerating the development of new therapies.
Is Recursion Pharmaceuticals publicly traded?
Yes, Recursion Pharmaceuticals is publicly traded on the Nasdaq under the ticker symbol RXRX. The company went public in April 2021, allowing it to raise capital to fund its ambitious drug discovery initiatives and expand its reach within the biotechnology industry.
What are the competitive advantages of Recursion Pharmaceuticals?
Recursion Pharmaceuticals' competitive advantages include its unique integration of machine learning with high-throughput biology, a robust data set from diverse biological experiments, and a talented team of professionals with expertise across various fields. These factors enable the company to accelerate drug discovery and optimize the development process, setting it apart from traditional pharmaceutical companies.
What areas of medicine does Recursion focus on?
Recursion Pharmaceuticals primarily focuses on rare diseases, as well as other therapeutic areas such as oncology and neurology. By concentrating on conditions that have historically been neglected, the company aims to unlock new treatment possibilities and improve outcomes for patients facing significant health challenges.
What does Recursion Pharmaceuticals, Inc. do?
Recursion Pharmaceuticals, Inc. is a biotechnology company that leverages advanced technology and machine learning to discover and develop new drug candidates for a wide range of diseases. The company's innovative platform integrates biology, chemistry, and data science to accelerate the drug discovery process, ultimately aiming to unveil treatments for challenging medical conditions, particularly rare diseases.
What is Recursion's vision?
Recursion Pharmaceuticals envisions a future where technology and biology intersect to transform how we approach drug discovery. The company's mission is to radically improve the speed and precision of developing treatments for diseases that currently lack effective therapies, ultimately fostering a deeper understanding of human biology and diseases.
What is the significance of machine learning for Recursion Pharmaceuticals?
Machine learning is central to Recursion Pharmaceuticals' operations as it enables the analysis of vast amounts of biological data to identify potential drug candidates more efficiently. By utilizing algorithms that can learn from and make predictions based on data, Recursion significantly shortens the drug discovery timeline and enhances the accuracy of its findings, leading to better-informed decision-making.
What is the status of Recursion's pipeline?
As of the latest updates, Recursion Pharmaceuticals has several drug candidates in various stages of clinical development. The pipeline includes potential treatments for a range of diseases, which are being evaluated through preclinical studies and clinical trials, showcasing the company's commitment to delivering innovative therapies.
What kind of funding has Recursion Pharmaceuticals received?
Recursion Pharmaceuticals has received substantial funding through various investment rounds, including venture capital and its initial public offering (IPO). The investments support its robust drug discovery platform, clinical trials, and technological advancements in the field of biotechnology.
What partnerships does Recursion have?
Recursion Pharmaceuticals has established multiple partnerships with academic institutions, researchers, and pharmaceutical companies. These collaborations are often focused on specific research projects, leveraging shared expertise and resources to enhance the drug discovery process and increase the chances of successful clinical outcomes.
What patient populations does Recursion target with its therapies?
Recursion Pharmaceuticals primarily targets patient populations affected by rare diseases, but it also explores therapies for broader conditions such as cancers and neurodegenerative disorders. By addressing unmet medical needs, Recursion aims to provide hope and therapeutic options to patients who previously had none.
What sets Recursion apart from traditional biotech companies?
What sets Recursion Pharmaceuticals apart from traditional biotech companies is its innovative approach that leverages computational biology and artificial intelligence. This combination allows Recursion to process complex biological data at an unprecedented scale, fostering a more agile and data-driven drug discovery process that contrasts sharply with conventional methods.
What technology does Recursion Pharmaceuticals use?
Recursion Pharmaceuticals utilizes a proprietary platform that combines advanced imaging technologies, machine learning, and biological assays. This approach allows the company to analyze large datasets and extract meaningful insights for drug discovery, significantly enhancing the speed and efficiency of identifying promising drug candidates.
When was Recursion Pharmaceuticals founded?
Recursion Pharmaceuticals was founded in 2013. Since its inception, the company has positioned itself as a pioneer in using high-throughput biology and artificial intelligence to create new therapeutic solutions, rapidly adapting its technological advances in response to the evolving landscape of drug discovery.
Where is Recursion Pharmaceuticals headquartered?
Recursion Pharmaceuticals is headquartered in Salt Lake City, Utah. This strategic location allows the company to tap into a growing biotechnology ecosystem while providing access to a skilled workforce in the life sciences and technology sectors.
Who are the leadership team members at Recursion Pharmaceuticals?
The leadership team at Recursion Pharmaceuticals consists of experienced professionals from diverse scientific and business backgrounds. Key members include co-founder and CEO Chris Gibson, who has extensive experience in both biotech and business, aiming to steer the company towards its vision of transforming drug discovery.
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 4.810
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 4:00 pm EDT on April 3rd, 2025